Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Reprints and Permissions
	Copyright Information
	Books from ASM Press
	MicrobeWorld

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Condra, J. H.
	Articles by Emini, E. A.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Condra, J. H.
	Articles by Emini, E. A.

J. Virol., Dec 1996, 8270-8276, Vol 70, No. 12
Copyright © 1996, American Society for Microbiology

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

JH Condra, DJ Holder, WA Schleif, OM Blahy, RM Danovich, LJ Gabryelski, DJ Graham, D Laird, JC Quintero, A Rhodes, HL Robbins, E Roth, M Shivaprakash, T Yang, JA Chodakewitz, PJ Deutsch, RY Leavitt, FE Massari, JW Mellors, KE Squires, RT Steigbigel, H Teppler and EA Emini
Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. jon_condra@merck.com.

Indinavir (IDV) (also called CRIXIVAN, MK-639, or L-735,524) is a potent and selective inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease. During early clinical trials, in which patients initiated therapy with suboptimal dosages of IDV, we monitored the emergence of viral resistance to the inhibitor by genotypic and phenotypic characterization of primary HIV-1 isolates. Development of resistance coincided with variable patterns of multiple substitutions among at least 11 protease amino acid residues. No single substitution was present in all resistant isolates, indicating that resistance evolves through multiple genetic pathways. Despite this complexity, all of 29 resistant isolates tested exhibited alteration of residues M-46 (to I or L) and/or V-82 (to A, F, or T), suggesting that screening of these residues may be useful in predicting the emergence of resistance. We also extended our previous finding that IDV-resistant viral variants exhibit various patterns of cross-resistance to a diverse panel of HIV- 1 protease inhibitors. Finally, we noted an association between the number of protease amino acid substitutions and the observed level of IDV resistance. No single substitution or pair of substitutions tested gave rise to measurable viral resistance to IDV. The evolution of this resistance was found to be cumulative, indicating the need for ongoing viral replication in this process. These observations strongly suggest that therapy should be initiated with the most efficacious regimen available, both to suppress viral spread and to inhibit the replication that is required for the evolution of resistance.

This article has been cited by other articles:

Margerison, E. S., Maguire, M., Pillay, D., Cane, P., Elston, R. C. (2008). The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication. J Antimicrob Chemother 61: 786-791 [Abstract] [Full Text]
Poon, A. F. Y., Kosakovsky Pond, S. L., Richman, D. D., Frost, S. D. W. (2007). Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients. J. Virol. 81: 13598-13607 [Abstract] [Full Text]
Mueller, S. M., Schaetz, B., Eismann, K., Bergmann, S., Bauerle, M., Schmitt-Haendle, M., Walter, H., Schmidt, B., Korn, K., Sticht, H., Spriewald, B., Harrer, E. G., Harrer, T. (2007). Dual Selection Pressure by Drugs and HLA Class I-Restricted Immune Responses on Human Immunodeficiency Virus Type 1 Protease. J. Virol. 81: 2887-2898 [Abstract] [Full Text]
Doron-Faigenboim, A., Pupko, T. (2007). A Combined Empirical and Mechanistic Codon Model. Mol Biol Evol 24: 388-397 [Abstract] [Full Text]
Edwards, C. T. T., Holmes, E. C., Pybus, O. G., Wilson, D. J., Viscidi, R. P., Abrams, E. J., Phillips, R. E., Drummond, A. J. (2006). Evolution of the Human Immunodeficiency Virus Envelope Gene Is Dominated by Purifying Selection. Genetics 174: 1441-1453 [Abstract] [Full Text]
Gonzalez, L. M. F., Aguiar, R. S., Afonso, A., Brindeiro, P. A., Arruda, M. B., Soares, M. A., Brindeiro, R. M., Tanuri, A. (2006). Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.. J. Gen. Virol. 87: 1303-1309 [Abstract] [Full Text]
Resch, W., Parkin, N., Watkins, T., Harris, J., Swanstrom, R. (2005). Evolution of Human Immunodeficiency Virus Type 1 Protease Genotypes and Phenotypes In Vivo under Selective Pressure of the Protease Inhibitor Ritonavir. J. Virol. 79: 10638-10649 [Abstract] [Full Text]
Marcelin, A.-G., Cohen-Codar, I., King, M. S., Colson, P., Guillevic, E., Descamps, D., Lamotte, C., Schneider, V., Ritter, J., Segondy, M., Peigue-Lafeuille, H., Morand-Joubert, L., Schmuck, A., Ruffault, A., Palmer, P., Chaix, M.-L., Mackiewicz, V., Brodard, V., Izopet, J., Cottalorda, J., Kohli, E., Chauvin, J.-P., Kempf, D. J., Peytavin, G., Calvez, V. (2005). Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 49: 1720-1726 [Abstract] [Full Text]
Svicher, V., Ceccherini-Silberstein, F., Erba, F., Santoro, M., Gori, C., Bellocchi, M. C., Giannella, S., Trotta, M. P., Monforte, A. d., Antinori, A., Perno, C. F. (2005). Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 49: 2015-2025 [Abstract] [Full Text]
Ludmerer, S. W., Graham, D. J., Boots, E., Murray, E. M., Simcoe, A., Markel, E. J., Grobler, J. A., Flores, O. A., Olsen, D. B., Hazuda, D. J., LaFemina, R. L. (2005). Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay. Antimicrob. Agents Chemother. 49: 2059-2069 [Abstract] [Full Text]
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T. Jr., Dewar, R. L., Metcalf, J. A., Hammer, S., Mellors, J. W., Coffin, J. M. (2005). Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis. J. Clin. Microbiol. 43: 406-413 [Abstract] [Full Text]
Kapoor, A., Jones, M., Shafer, R. W., Rhee, S.-Y., Kazanjian, P., Delwart, E. L. (2004). Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay. J. Virol. 78: 7112-7123 [Abstract] [Full Text]
Charpentier, C., Dwyer, D. E., Mammano, F., Lecossier, D., Clavel, F., Hance, A. J. (2004). Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors. J. Virol. 78: 4234-4247 [Abstract] [Full Text]
Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K., Sugiura, W. (2004). Gag Non-Cleavage Site Mutations Contribute to Full Recovery of Viral Fitness in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 444-452 [Abstract] [Full Text]
Rhodes, T., Wargo, H., Hu, W.-S. (2003). High Rates of Human Immunodeficiency Virus Type 1 Recombination: Near-Random Segregation of Markers One Kilobase Apart in One Round of Viral Replication. J. Virol. 77: 11193-11200 [Abstract] [Full Text]
Campo, R. E., Lichtenberger, P. N., Rosa, I., Suarez, G., Rivera, F. A., Rodriguez, A. E., Jayaweera, D. T., Wahlay, N. A., Kolber, M. A. (2003). Differences in the Frequency of Resistance to Antiretroviral Drug Classes among Human Immunodeficiency Virus Type 1 Clinical Isolates. J. Clin. Microbiol. 41: 3376-3378 [Abstract] [Full Text]
Karlsson, A. C., Deeks, S. G., Barbour, J. D., Heiken, B. D., Younger, S. R., Hoh, R., Lane, M., Sallberg, M., Ortiz, G. M., Demarest, J. F., Liegler, T., Grant, R. M., Martin, J. N., Nixon, D. F. (2003). Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. J. Virol. 77: 6743-6752 [Abstract] [Full Text]
Wu, T. D., Schiffer, C. A., Gonzales, M. J., Taylor, J., Kantor, R., Chou, S., Israelski, D., Zolopa, A. R., Fessel, W. J., Shafer, R. W. (2003). Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments. J. Virol. 77: 4836-4847 [Abstract] [Full Text]
Watkins, T., Resch, W., Irlbeck, D., Swanstrom, R. (2003). Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 47: 759-769 [Abstract] [Full Text]
Matsuoka-Aizawa, S., Sato, H., Hachiya, A., Tsuchiya, K., Takebe, Y., Gatanaga, H., Kimura, S., Oka, S. (2002). Isolation and Molecular Characterization of a Nelfinavir (NFV)-Resistant Human Immunodeficiency Virus Type 1 That Exhibits NFV-Dependent Enhancement of Replication. J. Virol. 77: 318-327 [Abstract] [Full Text]
Bernard, L., Vuagnat, A., Peytavin, G., Hallouin, M.-C., Bouhour, D., Nguyen, T. H., Vilde, J. L., Bricaire, F., Raguin, G., de Truchis, P., Ghez, D., Duong, M., Perronne, C. (2002). Relationship between Levels of Indinavir in Hair and Virologic Response to Highly Active Antiretroviral Therapy. ANN INTERN MED 137: 656-659 [Abstract] [Full Text]
Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]
Cuevas, J. M., Elena, S. F., Moya, A. (2002). Molecular Basis of Adaptive Convergence in Experimental Populations of RNA Viruses. Genetics 162: 533-542 [Abstract] [Full Text]
Piana, S., Carloni, P., Rothlisberger, U. (2002). Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11: 2393-2402 [Abstract] [Full Text]
Hammer, S. M., Vaida, F., Bennett, K. K., Holohan, M. K., Sheiner, L., Eron, J. J., Wheat, L. J., Mitsuyasu, R. T., Gulick, R. M., Valentine, F. T., Aberg, J. A., Rogers, M. D., Karol, C. N., Saah, A. J., Lewis, R. H., Bessen, L. J., Brosgart, C., DeGruttola, V., Mellors, J. W., for the AIDS Clinical Trials Group 398 Study Team, (2002). Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial. JAMA 288: 169-180 [Abstract] [Full Text]
Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]
Beck, I. A., Mahalanabis, M., Pepper, G., Wright, A., Hamilton, S., Langston, E., Frenkel, L. M. (2002). Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors. J. Clin. Microbiol. 40: 1413-1419 [Abstract] [Full Text]
Maguire, M., Shortino, D., Klein, A., Harris, W., Manohitharajah, V., Tisdale, M., Elston, R., Yeo, J., Randall, S., Xu, F., Parker, H., May, J., Snowden, W. (2002). Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors. Antimicrob. Agents Chemother. 46: 731-738 [Abstract] [Full Text]
Yoshimura, K., Kato, R., Kavlick, M. F., Nguyen, A., Maroun, V., Maeda, K., Hussain, K. A., Ghosh, A. K., Gulnik, S. V., Erickson, J. W., Mitsuya, H. (2002). A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site. J. Virol. 76: 1349-1358 [Abstract] [Full Text]
Dauber, D. S., Ziermann, R., Parkin, N., Maly, D. J., Mahrus, S., Harris, J. L., Ellman, J. A., Petropoulos, C., Craik, C. S. (2002). Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease. J. Virol. 76: 1359-1368 [Abstract] [Full Text]
Kaltenbach, R. F. III, Trainor, G., Getman, D., Harris, G., Garber, S., Cordova, B., Bacheler, L., Jeffrey, S., Logue, K., Cawood, P., Klabe, R., Diamond, S., Davies, M., Saye, J., Jona, J., Erickson-Viitanen, S. (2001). DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants. Antimicrob. Agents Chemother. 45: 3021-3028 [Abstract] [Full Text]
Palumbi, S. R. (2001). Humans as the World's Greatest Evolutionary Force. Science 293: 1786-1790 [Abstract] [Full Text]
Kempf, D. J., Isaacson, J. D., King, M. S., Brun, S. C., Xu, Y., Real, K., Bernstein, B. M., Japour, A. J., Sun, E., Rode, R. A. (2001). Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients. J. Virol. 75: 7462-7469 [Abstract] [Full Text]
Hance, A. J., Lemiale, V., Izopet, J., Lecossier, D., Joly, V., Massip, P., Mammano, F., Descamps, D., Brun-Vezinet, F., Clavel, F. (2001). Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy. J. Virol. 75: 6410-6417 [Abstract] [Full Text]
Frost, S. D. W., Dumaurier, M.-J., Wain-Hobson, S., Brown, A. J. L. (2001). Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc. Natl. Acad. Sci. USA 10.1073/pnas.131056998v1 [Abstract] [Full Text]
Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C. (2001). Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob. Agents Chemother. 45: 893-900 [Abstract] [Full Text]
La Seta Catamancio, S., De Pasquale, M. P., Citterio, P., Kurtagic, S., Galli, M., Rusconi, S. (2001). In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure. J. Clin. Microbiol. 39: 1124-1129 [Abstract] [Full Text]
Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C. (2001). Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy. J. Clin. Microbiol. 39: 454-459 [Abstract] [Full Text]
O'Meara, D., Wilbe, K., Leitner, T., Hejdeman, B., Albert, J., Lundeberg, J. (2001). Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing. J. Clin. Microbiol. 39: 464-473 [Abstract] [Full Text]
Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]
Martinez-Picado, J., DePasquale, M. P., Kartsonis, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Gunthard, H. F., Sutton, L., Savara, A., Petropoulos, C. J., Hellmann, N., Walker, B. D., Richman, D. D., Siliciano, R., D'Aquila, R. T. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97: 10948-10953 [Abstract] [Full Text]
Gulick, R. M. (2000). Assessing the Benefits of Antiretroviral Therapy. ANN INTERN MED 133: 471-473 [Full Text]
Mammano, F., Trouplin, V., Zennou, V., Clavel, F. (2000). Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug. J. Virol. 74: 8524-8531 [Abstract] [Full Text]
Gong, Y.-F., Robinson, B. S., Rose, R. E., Deminie, C., Spicer, T. P., Stock, D., Colonno, R. J., Lin, P.-f. (2000). In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632. Antimicrob. Agents Chemother. 44: 2319-2326 [Abstract] [Full Text]
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., Becker, M. F., Lasut, A. L., George, H. J., Spalding, D. R., Hollis, G., Abremski, K. (2000). Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy. Antimicrob. Agents Chemother. 44: 2475-2484 [Abstract] [Full Text]
Robinson, B. S., Riccardi, K. A., Gong, Y.-f., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., Lin, P.-f. (2000). BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrob. Agents Chemother. 44: 2093-2099 [Abstract] [Full Text]
Wilson, J. W., Bean, P., Robins, T., Graziano, F., Persing, D. H. (2000). Comparative Evaluation of Three Human Immunodeficiency Virus Genotyping Systems: the HIV-GenotypR Method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay. J. Clin. Microbiol. 38: 3022-3028 [Abstract] [Full Text]
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Meibohm, A., Condra, J. H., Valentine, F. T., McMahon, D., Gonzalez, C., Jonas, L., Emini, E. A., Chodakewitz, J. A., Isaacs, R., Richman, D. D. (2000). 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine. ANN INTERN MED 133: 35-39 [Abstract] [Full Text]
Lu, W., Andrieu, J.-M. (2000). HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 96: 250-258 [Abstract] [Full Text]
Rusconi, S., La Seta Catamancio, S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., d'Arminio-Monforte, A. (2000). Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 1328-1332 [Abstract] [Full Text]
Helbert, M., Breuer, J. (2000). Monitoring patients with HIV disease. J. Clin. Pathol. 53: 266-272 [Full Text]
Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J. P., Pialoux, G., Raffi, F., Brun-Vezinet, F., for the Trilege Study Team, (2000). Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy. JAMA 283: 205-211 [Abstract] [Full Text]
Havlir, D. V., Hellmann, N. S., Petropoulos, C. J., Whitcomb, J. M., Collier, A. C., Hirsch, M. S., Tebas, P., Sommadossi, J.-P., Richman, D. D. (2000). Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA 283: 229-234 [Abstract] [Full Text]
Ibáñez, A., Clotet, B., Martínez, M.-A. (2000). Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J. Gen. Virol. 81: 85-95 [Abstract] [Full Text]
Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., Katzenstein, D., Merigan, T. C., Efron, B. (1999). HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed. ANN INTERN MED 131: 813-821 [Abstract] [Full Text]
Rouzine, I. M., Coffin, J. M. (1999). Search for the Mechanism of Genetic Variation in the pro Gene of Human Immunodeficiency Virus. J. Virol. 73: 8167-8178 [Abstract] [Full Text]
Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., Markowitz, M. (1999). HIV-1 Drug Resistance in Newly Infected Individuals. JAMA 282: 1135-1141 [Abstract] [Full Text]
Bossi, P., Mouroux, M., Yvon, A., Bricaire, F., Agut, H., Huraux, J.-M., Katlama, C., Calvez, V. (1999). Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor. J. Clin. Microbiol. 37: 2910-2912 [Abstract] [Full Text]
Martinez-Picado, J., Sutton, L., De Pasquale, M. P., Savara, A. V., D'Aquila, R. T. (1999). Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing. J. Clin. Microbiol. 37: 2943-2951 [Abstract] [Full Text]
Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., vanOlden, A. L., Kuo, L. C. (1999). Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors. J. Biol. Chem. 274: 23699-23701 [Abstract] [Full Text]
Larder, B. A., Bloor, S., Kemp, S. D., Hertogs, K., Desmet, R. L., Miller, V., Sturmer, M., Staszewski, S., Ren, J., Stammers, D. K., Stuart, D. I., Pauwels, R. (1999). A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance. Antimicrob. Agents Chemother. 43: 1961-1967 [Abstract] [Full Text]
Shafer, R. W., Hsu, P., Patick, A. K., Craig, C., Brendel, V. (1999). Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1�Isolates from Patients Treated with Protease Inhibitors. J. Virol. 73: 6197-6202 [Abstract] [Full Text]
Martinez-Picado, J., Savara, A. V., Sutton, L., D'Aquila, R. T. (1999). Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1. J. Virol. 73: 3744-3752 [Abstract] [Full Text]
de la Carrière, L. C., Paulous, S., Clavel, F., Mammano, F. (1999). Effects of Human Immunodeficiency Virus Type 1�Resistance to Protease Inhibitors on Reverse Transcriptase Processing, Activity, and Drug Sensitivity. J. Virol. 73: 3455-3459 [Abstract] [Full Text]
Tanuri, A., Vicente, A. C.�P., Otsuki, K., Ramos, C. A., Ferreira, O. C. Jr., Schechter, M., Janini, L. M., Pieniazek, D., Rayfield, M. A. (1999). Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil. Antimicrob. Agents Chemother. 43: 253-258 [Abstract] [Full Text]
Arakaki, R., Tamamura, H., Premanathan, M., Kanbara, K., Ramanan, S., Mochizuki, K., Baba, M., Fujii, N., Nakashima, H. (1999). T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure. J. Virol. 73: 1719-1723 [Abstract] [Full Text]
Dulioust, A., Paulous, S., Guillemot, L., Delavalle, A.-M., Boue, F., Clavel, F. (1999). Constrained Evolution of Human Immunodeficiency Virus Type 1�Protease during Sequential Therapy with Two Distinct Protease Inhibitors. J. Virol. 73: 850-854 [Abstract] [Full Text]
Melnick, L., Yang, S.-S., Rossi, R., Zepp, C., Heefner, D. (1998). An Escherichia coli Expression Assay and Screen for Human Immunodeficiency Virus Protease Variants with Decreased Susceptibility to Indinavir. Antimicrob. Agents Chemother. 42: 3256-3265 [Abstract] [Full Text]
Nijhuis, M., Boucher, C. A.�B., Schipper, P., Leitner, T., Schuurman, R., Albert, J. (1998). Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95: 14441-14446 [Abstract] [Full Text]
Boden, D., Markowitz, M. (1998). Resistance to Human Immunodeficiency Virus Type 1�Protease Inhibitors. Antimicrob. Agents Chemother. 42: 2775-2783 [Full Text]
Patick, A. K., Potts, K. E. (1998). Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev. 11: 614-627 [Abstract] [Full Text]
Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M. R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D. R., Markowitz, M. (1998). Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1�Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir. Antimicrob. Agents Chemother. 42: 2637-2644 [Abstract] [Full Text]
Carrillo, A., Stewart, K. D., Sham, H. L., Norbeck, D. W., Kohlbrenner, W. E., Leonard, J. M., Kempf, D. J., Molla, A. (1998). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1�Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor. J. Virol. 72: 7532-7541 [Abstract] [Full Text]
Mammano, F., Petit, C., Clavel, F. (1998). Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease and gag Coevolution in Protease Inhibitor-Treated Patients. J. Virol. 72: 7632-7637 [Abstract] [Full Text]
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif, W. A., Condra, J. H., Emini, E. A., Isaacs, R., Chodakewitz, J. A., Richman, D. D. (1998). Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection: 100-Week Follow-up. JAMA 280: 35-41 [Abstract] [Full Text]
Eastman, P. S., Mittler, J., Kelso, R., Gee, C., Boyer, E., Kolberg, J., Urdea, M., Leonard, J. M., Norbeck, D. W., Mo, H., Markowitz, M. (1998). Genotypic Changes in Human Immunodeficiency Virus Type 1�Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy. J. Virol. 72: 5154-5164 [Abstract] [Full Text]
Winters, M. A., Schapiro, J. M., Lawrence, J., Merigan, T. C. (1998). Human Immunodeficiency Virus Type 1�Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment. J. Virol. 72: 5303-5306 [Abstract] [Full Text]
Wang, W.-K., Dudek, T., Zhao, Y.-J., Brumblay, H. G., Essex, M., Lee, T.-H. (1998). CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1�gp120. Proc. Natl. Acad. Sci. USA 95: 5740-5745 [Abstract] [Full Text]
Zennou, V., Mammano, F., Paulous, S., Mathez, D., Clavel, F. (1998). Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1�Variants Selected for Resistance to Protease Inhibitors In Vivo. J. Virol. 72: 3300-3306 [Abstract] [Full Text]
Gulick, R. M. (1998). HIV Treatment Strategies: Planning for the Long Term. JAMA 279: 957-959 [Full Text]
Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., Peeters, F., Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., Pauwels, R. (1998). A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1�Isolates from Patients Treated with Antiretroviral Drugs. Antimicrob. Agents Chemother. 42: 269-276 [Abstract] [Full Text]
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., Siliciano, R. F. (1997). Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy. Science 278: 1295-1300 [Abstract] [Full Text]
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., Chodakewitz, J. A., Deutsch, P., Holder, D., Schleif, W. A., Condra, J. H. (1997). Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. NEJM 337: 734-739 [Abstract] [Full Text]
Frost, S. D. W., Dumaurier, M.-J., Wain-Hobson, S., Brown, A. J. L. (2001). Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc. Natl. Acad. Sci. USA 98: 6975-6980 [Abstract] [Full Text]

J. Bacteriol.	Mol. Cell. Biol.	Microbiol. Mol. Biol. Rev.

Clin. Vaccine Immunol.	ALL ASM JOURNALS